secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-05-11T20:05:17+00:00
Accession:  0001193125-26-216735
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q2 FY2026 net loss narrows to $13.1M; Phase 1 trial started for EDP-978
------------------------------------------------------------------------------

- Revenue $17.2M from AbbVie royalties (up from $14.9M YoY); net loss $13.1M ($0.45/share) vs $22.6M loss YoY.
- Cash $227M; runway into fiscal 2029; R&D spend $19.4M (down from $28.1M due to lower RSV trial costs).
- Phase 1 dosing initiated for oral KIT inhibitor EDP-978; topline data expected Q4 2026.
- Zelicapavir pivotal study enabling with FDA; update planned in Q2 2026; exploring BD opportunities.
- Litigation: Federal Circuit oral arguments vs Pfizer; decision by Sept 2026; UPC hearing Sept 29.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/0001193125-26-216735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer